IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.

Andere talen ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Aandelen

1541

CNE100006624

Beurs gesloten - Hong Kong S.E. Andere beurzen 10:08:22 10-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
14,58 ^HKD	-2,15%		-1,09%	-51,24%

17/04	ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Ontvangt goedkeuring van de National Medical Products Administration van de Volksrepubliek China voor het protocol van de fase Iii klinische studie van IMM01	CI
26/03	Immuneonco Biopharmaceuticals' verlies in 2023 daalt terwijl andere inkomsten stijgen	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

ImmuneOnco Obtains Chinese Nod for Phase III Trials of Anti-Cancer Medication	17/04
ImmuneOnco Biopharmaceuticals Inc. Receives Approval from the National Medical Products Administration of the People's Republic of China for the Protocol of the Phase Iii Clinical Trial of IMM01	17/04
Immuneonco Biopharmaceuticals' 2023 Loss Narrows as Other Income Increases	26/03
ImmuneOnco Biopharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	25/03
Immuneonco Biopharmaceuticals CFO Resigns	04/03
Immuneonco Biopharmaceuticals Inc. Announces Board and Executive Changes	01/03
ImmuneOnco Begins Phase II Clinical Trial of Anti-Tumor Drug	20/11
ImmuneOnco Biopharmaceuticals Inc. Announces First Patient Dosed in the Phase II Clinical Trial of IMM2510 for the Treatment of Refractory or Relapsed Alveolar Soft Part Sarcoma	20/11
ImmuneOnco Biopharmaceuticals Gets US FDA's Orphan-Drug Designation for Leukemia Drug Combination	09/11
ImmuneOnco Biopharmaceuticals Gets Nod to Trial Cancer Drug	07/11
ImmuneOnco Biopharmaceuticals Inc. Receives an Investigational New Drug Approval from the National Medical Products Administration of the People's Republic of China	07/11
ImmuneOnco to Present Results of Anti-Cancer Drug Studies at American Convention	06/11
China Grants Investigational New Drug Approval to ImmuneOnco's Cancer Treatment; Shares Fall 4%	16-10-23
ImmuneOnco Biopharmaceuticals Inc. Obtains an Investigational New Drug Approval for IMM47 for the Treatment of Solid Tumors from the National Medical Products Administration of the People's Republic of China	16-10-23
ImmuneOnco to Raise Near HK$17 Million from Over-Allotment of Shares	29-09-23
Immuneonco Biopharmaceuticals Inc. Provides Updates on the Clinical Trial of Imm47	27-09-23
ImmuneOnco Biopharma Completes Patient Enrollment for Phase 1 Study of Two Antitumor Medications	12-09-23
ImmuneOnco Biopharmaceuticals Inc. Provides Updates on the Clinical Trials of IMM2510 and IMM27M	11-09-23
Hong Kong Stocks Retreat On Fears Over China Property Default; ImmuneOnco Biopharmaceuticals Gains 5%	05-09-23
ImmuneOnco Biopharmaceuticals Inc. has completed an IPO in the amount of HKD 318.93792 million.	04-09-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Aandelen

1541

CNE100006624

Andere talen

Filters